ReviewCancer science2026
PEGylated Chitosan Nanoparticles: Engineering Multifunctional Platforms for Targeted Cervical and Lung Cancer Treatment.
Review in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chitosan in Modern Pharmacotherapy: Chitosan Nanoparticles and Delivery Systems.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Polymer-based nanocarriers have emerged as transformative platforms in cancer nanomedicine, enabling controlled and site-specific delivery of therapeutic agents. Among polysaccharide-derived materials, chitosan stands out for its biodegradability, biocompatibility, and intrinsic mucoadhesive properties that promote efficient drug encapsulation and enhanced cellular internalization. Surface PEGylation the conjugation of polyethylene glycol (PEG) chains further augments the physicochemical and biological performance of chitosan nanoparticles by enhancing colloidal stability, extending systemic circulation, and reducing opsonization by the reticuloendothelial system. In addition, ligand-mediated functionalization facilitates active tumor targeting and selective intracellular delivery, thereby improving therapeutic efficacy while minimizing off-target toxicity. This review critically summarizes recent advances in the design, synthesis, and functional modification of PEGylated chitosan nanoparticles, with emphasis on their pharmacokinetic behavior, drug release mechanisms, and anticancer performance. Comparative insights into other polymeric and lipid-based nanocarrier systems are also provided. Finally, current challenges, safety considerations, and translational perspectives are discussed, underscoring the promise of PEGylated chitosan nanoplatforms as next-generation biomaterials for precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.